Target Name: CDC14A
NCBI ID: G8556
Review Report on CDC14A Target / Biomarker Content of Review Report on CDC14A Target / Biomarker
CDC14A
Other Name(s): CDC14 cell division cycle 14 homolog A | CDC10 (cell division cycle 10, S. cerevisiae, homolog) | CDC14A variant 2 | Dual specificity protein phosphatase CDC14A | CDC14A variant 1 | cdc14 | Cell division cycle 14A, transcript variant 1 | cell division cycle 14A | CC14A_HUMAN | deafness, autosomal recessive 32 | Dual specificity protein phosphatase CDC14A (isoform 2) | Cell division cycle 14A, transcript variant 2 | CDC14A variant 3 | Dual specificity protein phosphatase CDC14A (isoform 1) | DFNB35 | DFNB105 | Dual specificity protein phosphatase CDC14A (isoform 3) | deafness | Cell division cycle 14A, transcript variant 3 | OTTHUMP00000012656 | autosomal recessive 32 | hCDC14 | DFNB32

CD14A: A Promising Drug Target and Biomarker for Cancer Treatment

Introduction

Cancer is one of the leading causes of morbidity and mortality worldwide, affecting millions of people every year. The rapid growth of cancer cells has transformed into a disease that seriously threatens human health. CDC14A (CDC14 cell division cycle 14 homolog A), a gene located on chromosome 14, has been identified as a potential drug target and biomarker for cancer treatment. In this article, we will explore the biology of CDC14A, its potential as a drug target , and its potential as a biomarker for cancer diagnosis and treatment.

biological background

CDC14A is a gene belonging to the CDC14 gene family and is located on chromosome 14. The CDC14 gene family includes many genes that play important biological roles in the cell mitotic cycle. CDC14A is in the S phase of the mitotic cycle and is a key step in the cell cycle.

CDC14A is expressed in various cancers

CDC14A is expressed in a variety of cancers, including breast cancer, lung cancer, prostate cancer, and colon cancer. Studies have shown that the expression level of CDC14A is closely related to the prognosis and treatment response of cancer.

Pharmacological significance of CDC14A

CDC14A is of high pharmacological significance as a potential drug target. Research shows that CDC14A can be used as a drug target to treat a variety of cancers, including breast, lung, prostate and colon cancer.

Biological significance of CDC14A

CDC14A plays an important role in the cell mitosis cycle and is closely related to the cell cycle and tumor development. Studies have shown that the activity and expression level of CDC14A are closely related to the invasion and metastasis capabilities of tumors. In addition, the expression level of CDC14A is also closely related to the immune evasion ability of tumors.

Clinical significance of CDC14A

As a potential drug target and biomarker, CDC14A has high clinical significance in cancer treatment. Studies have shown that the expression level of CDC14A can be used as an important indicator to evaluate the prognosis of cancer patients. In addition, the expression level of CDC14A can also be used as an indicator to evaluate the immune evasion ability of tumors.

Therapeutic prospects of CDC14A

With the discovery of CDC14A as a potential drug target and biomarker, the field of cancer treatment is rapidly evolving. Currently, many CDC14A-related clinical trials are ongoing to evaluate the role of CDC14A in cancer treatment.

in conclusion

As a potential drug target and biomarker, CDC14A has high biological and clinical significance. With the discovery of CDC14A as a potential drug target and biomarker, the field of cancer treatment is rapidly evolving. Future research will continue to delve into the role of CDC14A in cancer treatment and provide better treatment options for cancer patients.

Protein Name: Cell Division Cycle 14A

Functions: Dual-specificity phosphatase. Required for centrosome separation and productive cytokinesis during cell division. Dephosphorylates SIRT2 around early anaphase. May dephosphorylate the APC subunit FZR1/CDH1, thereby promoting APC-FZR1 dependent degradation of mitotic cyclins and subsequent exit from mitosis. Required for normal hearing (PubMed:29293958)

The "CDC14A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDC14A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4